Two Local Articles on HIV Vaccine Research
There are two great local articles about HIV vaccine research, be sure to check them out. First, Metro Weekly has an article about Monday Night's presentation on HIV Vaccine Research organized by The Center. If you missed the event, it was a great night of fun and discussion at one my favorite local hangouts, the Ramrod.One of the hot topics of the night was the recent closure of a Merck vaccine study, known as the Step Study. While the failure of this study is disappointing, it is important to remember was just one of many approaches to HIV Vaccine Research currently being researched.
Which brings me to the Washington Blade Article on the Step Study. The article quotes one of many researchers involved in the study, Dr. Mark Mulligan from Atlanta's Hope Center:
“While disappointment was my main reaction, the next step is, OK, this is science and we’ve gotten a clear and strong answer what direction not to take,” Mulligan added. “We knew it might work, that it might not work. And we learn from that experience, so in that sense, it has been successful. Now we can throw our energy and efforts into other candidate vaccines.”
1 Comments:
Source: http://www.sciencedaily.com/releases/2007/10/071012080135.htm
Science Daily — The search for a vaccination against HIV has been in progress since 1984, with very little success. Traditional methods used for identifying potential cellular targets can be very costly and time-consuming.
The key to creating a vaccination lies in knowing which parts of the pathogen to target with which antibodies. A new study by David Heckerman and colleagues from Massachusetts General Hospital, publishing in PLoS Computational Biology, has come up with a way to match pathogens to their antibodies.
At the core of the human immune response is the train-to-kill mechanism in which specialized immune cells are sensitized to recognize small peptides from foreign pathogens (e.g., HIV). Following this sensitization, these cells are then activated to kill cells that display this same peptide. However, for sensitization and killing to occur, the pathogen peptide must be "paired up" with one of the infected person's other specialized immune molecules--an HLA (human leukocyte antigen) molecule. The way in which pathogen peptides interact with these HLA molecules defines if and how an immune response will be generated.
Heckerman's model uses ELISpot assays to identify HLA-restricted epitopes, and which HLA alleles are responsible for which reactions towards which pathogens. The data generated about the immune response to pathogens fills in missing information from previous studies, and can be used to solve a variety of similar problems.
The model was applied to data from donors with HIV, and made 12 correct predictions out of 16. This study, says David Heckerman, has "significant implications for the understanding of...vaccine development." The statistical approach is unusual in the study of HLA molecules, and could lead the way to developing an HIV vaccine.
Citation: Listgarten J, Frahm N, Kadie C, Brander C, Heckerman D (2007) A statistical framework for modeling HLA-dependent T cell response data. PLoS Comput Biol 3(10): e188. doi:10.1371/journal.pcbi.0030188
Note: This story has been adapted from material provided by Public Library of Science.
Fausto Intilla
www.oloscience.com
Post a Comment
Links to this post:
Create a Link
<< Home